Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $4.6 million.

  • C4 Therapeutics' Share-based Compensation fell 4799.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year decrease of 2547.93%. This contributed to the annual value of $29.7 million for FY2024, which is 891.13% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Share-based Compensation is $4.6 million, which was down 4799.0% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Share-based Compensation peaked at $8.9 million during Q1 2022, and registered a low of $3.8 million during Q1 2021.
  • Over the past 5 years, C4 Therapeutics' median Share-based Compensation value was $6.4 million (recorded in 2021), while the average stood at $6.5 million.
  • Per our database at Business Quant, C4 Therapeutics' Share-based Compensation surged by 321465.52% in 2021 and then tumbled by 4799.0% in 2025.
  • Over the past 5 years, C4 Therapeutics' Share-based Compensation (Quarter) stood at $6.4 million in 2021, then rose by 8.91% to $6.9 million in 2022, then dropped by 8.09% to $6.4 million in 2023, then increased by 29.5% to $8.2 million in 2024, then crashed by 44.23% to $4.6 million in 2025.
  • Its Share-based Compensation was $4.6 million in Q3 2025, compared to $5.0 million in Q2 2025 and $5.5 million in Q1 2025.